Results 31 to 40 of about 313,411 (354)

Lipoprotein(a) and inhibitors of proprotein convertase subtilisin/kexin type 9 [PDF]

Journal of Thoracic Disease, 2017
Lipoprotein(a) [Lp(a)] has been identified as a risk factor for cardiovascular disease. Lp(a) levels are also high under certain clinical conditions, including familial hypercholesterolemia and high blood low-density lipoprotein (LDL) cholesterol levels. Few effective generic therapies for modulating Lp(a) have been developed.
Maciej Banach, Kazuhiko Kotani
openaire   +3 more sources

Proprotein Convertase Subtilisin/Kexin Type 9 Promotes Gastric Cancer Metastasis and Suppresses Apoptosis by Facilitating MAPK Signaling Pathway Through HSP70 Up-Regulation

Frontiers in Oncology, 2021
Objective To examine the effect of proprotein convertase subtilisin/kexin type 9 (PCSK9) on gastric cancer (GC) progression and prognosis, and to explore the underlying mechanism.
Bei-li Xu, Shuyu Li, Yong Fang, Y. Zou, Dongqiang Song, Shuncai Zhang, Yu Cai   +6 more
semanticscholar   +1 more source

Proprotein convertase subtilisin/kexin type 9 and lipid metabolism [PDF]

Current Opinion in Lipidology, 2019
Purpose of review The purpose of this review is to highlight the recent findings of one of the most promising therapeutic targets in LDL cholesterol (LDL-C) management, proprotein convertase subtilisin/kexin type 9 (PCSK9).
John A Zadroga, Stefano Spolitu, Lale Ozcan, Wen Dai   +3 more
openaire   +3 more sources

Predictors and morphological properties of culprit healed plaques in patients with angina pectoris

Clinical Cardiology, Volume 45, Issue 12, Page 1199-1210, December 2022., 2022
Abstract Background Plaque healing may serve a vital function in the natural progression of atherosclerotic disease. This study sought to investigate predictors and morphological characteristics of healed plaque (HP) among angina pectoris (AP) patients.
Hongying Yao, Qianyun Guo, Yujing Cheng, Tianyu Zhu, Qian Ma, Yujie Zhou   +5 more
wiley   +1 more source

Use of lipid‐lowering therapies in patients with chronic kidney disease and atherosclerotic cardiovascular disease: 2‐year results from Getting to an imprOved Understanding of Low‐Density lipoprotein cholesterol and dyslipidemia management (GOULD)

Clinical Cardiology, Volume 45, Issue 12, Page 1303-1310, December 2022., 2022
Abstract Background Chronic kidney disease (CKD) is a known risk factor of atherosclerotic cardiovascular disease (ASCVD). Per the 2018 American Heart Association/American College of Cardiology cholesterol guidelines, high‐risk ASCVD patients with CKD and low‐density lipoprotein cholesterol (LDL‐C) levels ≥ $\ge $ 70 mg/dL should take a high‐intensity ...
Aleesha Shaik, Mikhail Kosiborod, James A. de Lemos, Qi Gao, Katherine E. Mues, Shushama Alam, Deepak L. Bhatt, Christopher P. Cannon, Christie M. Ballantyne, Robert S. Rosenson, The GOULD Investigators   +10 more
wiley   +1 more source

Serum Levels of PCSK9 Are Associated with Coronary Angiographic Severity in Patients with Acute Coronary Syndrome [PDF]

Diabetes & Metabolism Journal, 2018
BackgroundProprotein convertase subtilisin/kexin type 9 (PCSK9) is a circulating protein that promotes degradation of the low density lipoprotein receptor.
Kwi-Hyun Bae, Sung Woo Kim, Yeon-Kyung Choi, Jung Beom Seo, Namkyun Kim, Chang-Yeon Kim, Won Kee Lee, Sungwoo Lee, Jung Guk Kim, In-Kyu Lee, Jang Hoon Lee, Keun-Gyu Park   +11 more
doaj   +1 more source

New Insight Into Metformin-Induced Cholesterol-Lowering Effect Crosstalk Between Glucose and Cholesterol Homeostasis via ChREBP (Carbohydrate-Responsive Element-Binding Protein)-Mediated PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Regulation.

Arteriosclerosis, Thrombosis and Vascular Biology, 2021
OBJECTIVE Metformin, a first-line drug for treating individuals with type 2 diabetes, exerts beneficial effects on cholesterol-lowering, yet its precise mechanism has not been established.
Die Hu, Yanhong Guo, R. Wu, Tiannan Shao, Junke Long, Bilian Yu, Huilun Wang, Yonghong Luo, Haocheng Lu, Jifeng Zhang, Y. E. Chen, Daoquan Peng   +11 more
semanticscholar   +1 more source

PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Triggers Vascular Smooth Muscle Cell Senescence and Apoptosis: Implication of Its Direct Role in Degenerative Vascular Disease

Arteriosclerosis, Thrombosis and Vascular Biology, 2021
Supplemental Digital Content is available in the text. Objective: PCSK9 (proprotein convertase subtilisin/kexin type 9) plays a critical role in cholesterol metabolism via the PCSK9–LDLR (low-density lipoprotein receptor) axis in the liver; however ...
Yanan Guo, Zhi-Bin Tang, Binjie Yan, H. Yin, S. Tai, Juan Peng, Yuting Cui, Y. Gui, D. Belke, Shenghua Zhou, Xi-Long Zheng   +10 more
semanticscholar   +1 more source

Proprotein Convertase Subtilisin Kexin Type 9 Inhibitors Reduce Platelet Activation Modulating ox-LDL Pathways

International Journal of Molecular Sciences, 2021
Background: Proprotein convertase subtilisin kexin type 9 inhibitors (PCSK9i) lower LDL-cholesterol and slow atherosclerosis preventing cardiovascular events.
V. Cammisotto, F. Baratta, Valentina Castellani, S. Bartimoccia, C. Nocella, L. D’Erasmo, N. Cocomello, C. Barale, Roberto Scicali, A. Di Pino, S. Piro, M. del Ben, M. Arca, I. Russo, F. Purrello, R. Carnevale, F. Violi, D. Pastori, P. Pignatelli   +18 more
semanticscholar   +1 more source

Apolipoprotein F is reduced in humans with steatosis and controls plasma triglyceride‐rich lipoprotein metabolism

Hepatology, EarlyView., 2022
Hepatic APOF transcript levels correlate inversely with plasma TG and hepatic steatosis in humans. ApoF expression in mice promotes VLDL‐TG production and lipoprotein remnant clearance in mice. Abstract Background NAFLD affects nearly 25% of the global population. Cardiovascular disease (CVD) is the most common cause of death among patients with NAFLD,
Audrey Deprince, Nathalie Hennuyer, Sander Kooijman, Amanda C. M. Pronk, Eric Baugé, Viktor Lienard, An Verrijken, Eveline Dirinck, Luisa Vonghia, Eloïse Woitrain, Niels J. Kloosterhuis, Eléonore Marez, Pauline Jacquemain, Justina C. Wolters, Fanny Lalloyer, Delphine Eberlé, Sandrine Quemener, Emmanuelle Vallez, Anne Tailleux, Mostafa Kouach, Jean‐Francois Goossens, Violeta Raverdy, Bruno Derudas, Jan Albert Kuivenhoven, Mikaël Croyal, Bart van de Sluis, Sven Francque, François Pattou, Patrick C. N. Rensen, Bart Staels, Joel T. Haas   +30 more
wiley   +1 more source